The pharmaceutical and life sciences industry is undergoing a period of intense transformation driven by significant pressure for change from market forces, cost and profitability challenges, regulators, investors and the wider stakeholder group.
From diminishing product pipelines and escalating operating costs to calls for lower prices and a greater regulatory burden, the industry is confronting unprecedented challenges that are expected to radically transform its current business model. Life science companies also face increasingly tougher choices about product development strategy, funding sources, collaboration arrangements and the competition for talent.
PricewaterhouseCoopers is a leading provider of professional services to the pharmaceutical and life sciences sector, both internationally and in Ireland. Our specialists are dedicated to finding the most effective solutions to the challenges your business face.
Publications
Pharma 2020: The vision
By 2020, the environment in which the pharmaceutical industry operates will be very different from that which prevails today. Here we expose the issues likely to have a major bearing on the industry over the next 13 years together with the changes we believe will best help companies operate in this new environment and realise the potential the future holds.
>>> |
|
A review of the implementation of IFRS in the pharmaceuticals industry
The move to International Financial Reporting Standards (IFRS) has changed the way pharmaceutical companies present their business and are assessed by analysts, investors and other key users of their accounts. In this report we review financial statements of the 12 largest pharmaceutical entities to determine how they have applied the international standards to their business.
>>>
|
|
Gearing up for a global gravity shift: Growth, risk and learning in the Asia pharmaceutical market
Moving East? This report reveals that the centre of gravity of the global pharmaceutical industry is set to shift to Asia, a move which started as economies grew and continues today as companies increasingly seek to site research, development and clinical trial activity in the region.
>>>
|
|
Global CEO survey: Pharmaceutical and life sciences results
The central theme of our global survey is how CEOs perceive their current business environment and the impact of an increasingly connected world on the way companies work, grow, deal with risk and, ultimately, achieve business success. Here we focus on how pharmaceutical and life sciences executives view and are addressing a number of fundamental concerns facing the sector.
>>>
|
|
